TIAN YUAN HEALTHCARE
天元医疗

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED
中國天元醫療集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 557)

APPLICATION FOR WAIVER UNDER RULES 14.60A OF THE LISTING RULES

References are made to the announcement of the Company dated 31 December 2025 in relation to the proposed acquisition of 70% equity interest in the Target Company by the Purchaser from the Vendors for a consideration of RMB2,100,000, the announcement dated 8 January 2026 in relation to the Supplemental Agreement (the "**Announcements**"). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

As stated in the Announcements, the Company shall publish further announcement under Rule 14.60A on or before 22 January 2026.

Since additional time is required for the Company's auditors to prepare and finalise the letter from the Company's auditors in respect of the profit forecast of the Target Company, the Company has applied for a waiver from strict compliance with Rules 14.60A of the Listing Rules to extend the deadline of announcing and submitting the required information to the Stock Exchange under Rules 14.60A of the Listing Rules to 30 January 2026 (the "**Waiver**").

Further announcement(s) will be made by the Company in relation to the progress of the Waiver and the required information under Rules 14.60A of the Listing Rules as and when appropriate in accordance with the applicable rules and regulations.

Completion is conditional upon the satisfaction of certain Conditions Precedent stipulated in the Equity Transfer Agreement. There is no assurance that any of such conditions will be fulfilled. Accordingly, the Acquisition may or may not proceed. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
China Tian Yuan Healthcare Group Limited
Dong Wei
Executive Director

Hong Kong, 22 January 2026

As at the date of this announcement, the Board is composed of five directors of which Ms. Dong Wei is the executive Director, Ms. He Mei is the non-executive Director, and Mr. Yuen Kwok Kuen, Ms. Zhou Siqi and Mr. Li Jun are the independent non-executive Directors.